Your browser doesn't support javascript.
loading
Near-infrared light-responsive Nitric oxide microcarrier for multimodal tumor therapy.
Liang, Danna; Kuang, Gaizhen; Chen, Xiang; Lu, Jianhua; Shang, Luoran; Sun, Weijian.
Afiliação
  • Liang D; Department of Gastrointestinal Surgery The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
  • Kuang G; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health) Wenzhou Institute University of Chinese Academy of Sciences Wenzhou Zhejiang China.
  • Chen X; Department of Gastrointestinal Surgery The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
  • Lu J; Department of Gastrointestinal Surgery The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
  • Shang L; Department of Gastrointestinal Surgery The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
  • Sun W; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health) Wenzhou Institute University of Chinese Academy of Sciences Wenzhou Zhejiang China.
Smart Med ; 2(3): e20230016, 2023 Aug.
Article em En | MEDLINE | ID: mdl-39188343
ABSTRACT
Nitric oxide (NO) has shown great potential in tumor therapy, and the development of a platform for precise and controllable NO release still needs to be explored. Herein, a microfluidic electrospray strategy is proposed for the fabrication of hydrogel microspheres encapsulating NO donors (S-nitrosoglutathione, GSNO) together with black phosphorus (BP) and chemotherapeutic doxorubicin (DOX) as microcarriers for tumor therapy. Based on the excellent photothermal property of BP and thermal sensitivity of GSNO, the microcarriers exhibit a near-infrared light (NIR)-responsive NO release behavior. Besides, the photothermal performance of the microcarriers accelerates the release of DOX. All these contribute to the excellent tumor-killing effect of the microcarriers by combining multiple therapeutic strategies including NO therapy, photothermal therapy, and chemotherapy. Moreover, it was demonstrated that the NIR-responsive NO delivery microcarriers could significantly inhibit tumor growth without apparent side effects in vivo. Therefore, it is believed that the novel NIR-responsive NO microcarriers are promising candidates in clinical tumor therapy applications.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Smart Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Smart Med Ano de publicação: 2023 Tipo de documento: Article